PPAR-gamma agonists: a role in the prevention of chronic allograft nephropathy?
Serpieri, N.
Giornale Italiano di Nefrologia Organo Ufficiale Della Societa Italiana di Nefrologia 27(5): 446
2010
ISSN/ISBN: 0393-5590 PMID: 20922674 Document Number: 640156
Document emailed within 1 workday
Related Documents
Vázquez, M.; Silvestre, J.S.; Prous, J.R. 2002: Experimental approaches to study PPAR gamma agonists as antidiabetic drugs Methods and Findings in Experimental and Clinical Pharmacology 24(8): 515-523Takahara, S. 2002: Immunological factors for chronic rejection and the methods for the prevention of chronic allograft nephropathy Hinyokika Kiyo. Acta Urologica Japonica 48(11): 683-686
Fajas, L.; Debril, M.B.; Auwerx, J. 2001: PPAR gamma: an essential role in metabolic control Nutrition Metabolism and Cardiovascular Diseases: Nmcd 11(1): 64-69
Serón, D.; Moreso, F.; Ramón, J.M.; Hueso, M.; Condom, E.; Fulladosa, X.; Bover, J.; Gil-Vernet, S.; Castelao, A.M.; Alsina, J.; Grinyó, J.M. 2000: Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy Transplantation 69(9): 1849-1855
Klimek, D.; Chudek, J. 2001: Chronic allograft nephropathy Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 11(61): 95-98
Heinzl, S. 2006: Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists Medizinische Monatsschrift für Pharmazeuten 29(3): 93-96
Camejo, G.án. 2003: PPAR agonists in the treatment of insulin resistance and associated arterial disease International Journal of Clinical Practice. Suppl 134: 36-44
Nie, F.; Yang, Q.; Deng, K.; Sun, X.; Dong, J.; Li, Z. 2015: Acupuncture-moxibustion for chronic allograft nephropathy: a randomized controlled trial Zhongguo Zhen Jiu 35(11): 1110-1114
Knodell, R.G.; Conrad, M.E.; Ishak, K.G. 1977: Development of chronic liver disease after acute non-A, non-B post-transfusion hepatitis. Role of gamma-globulin prophylaxis in its prevention Gastroenterology 72(5 Pt 1): 902-909
Becker, B.N.; Jacobson, L.M.; Hullett, D.A.; Radke, N.A.; Oberley, T.D.; Brazy, P.C.; Kirk, A.D. 2002: Type 2 angiotensin II receptor expression in human renal allografts: an association with chronic allograft nephropathy Clinical Nephrology 57(1): 19-26
Butt, C.; Gladman, D.; Rahman, P. 2006: PPAR-gamma gene polymorphisms and psoriatic arthritis Journal of Rheumatology 33(8): 1631-1633
Bełtowski, J.; Wójcicka, G.; Jamroz, A. 2003: Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy Postepy Higieny i Medycyny Doswiadczalnej 57(2): 199-217
Zeng, X-Jian.; Bi, X-Cheng.; Dai, Q-Shan.; Han, Z-Dong.; Zhong, W-De. 2012: Effects of PPAR-gamma on the proliferation and glycolysis metabolism of prostate cancer cells Zhonghua Nan Ke Xue 18(8): 692-696
Yuan, Z.-y.; Liu, Y.; Liu, Y.; Zhang, J.-j.; Kishimoto, C.; Wang, Y.-n.; Ma, A.-q.; Liu, Z.-q. 2004: PPAR-gamma ligands inhibit the expression of inflammatory cytokines and attenuate autoimmune myocarditis Chinese Medical Journal 117(8): 1253-1255
Quattrin, N.; Dini, E.; Di Girolamo, R.; Ventruto, V. 1970: Atypical chronic lymphoproliferative disease with cold agglutininemia, cryoglobulinemia and gamma G, gamma A, gamma M, gamma D hyperglobulinemia Schweizerische Medizinische Wochenschrift 100(7): 306-308
Katayama, K.; Wada, K.; Nakajima, A.; Mizuguchi, H.; Hayakawa, T.; Nakagawa, S.; Kadowaki, T.; Nagai, R.; Kamisaki, Y.; Blumberg, R.S.; Mayumi, T. 2003: A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model Gastroenterology 124(5): 1315-1324
Ranhotra, H.S. 2010: Long-term caloric restriction up-regulates PPAR gamma co-activator 1 alpha (PGC-1alpha) expression in mice Indian Journal of Biochemistry and Biophysics 47(5): 272-277
Sanders, C.E.; Curtis, J.J. 1995: Role of hypertension in chronic renal allograft dysfunction Kidney International. Supplement 52: S43-S47
Gruszka, A.; Kunert-Radek, J.; Pawlikowski, M. 2005: Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro Neuro Endocrinology Letters 26(1): 51-54
Strakova, N.; Ehrmann, J.; Bartos, J.; Malikova, J.; Dolezel, J.; Kolar, Z. 2005: Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors Neoplasma 52(2): 126-136